At a glance
- Originator Fujisawa
- Class Anti-inflammatories
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Emphysema
Most Recent Events
- 30 May 2001 Profile reviewed but no significant changes made
- 23 Jun 1998 Commercial data has been reviewed by Fujisawa
- 17 Jun 1997 No-Development-Reported for Emphysema in Japan (Unknown route)